Close
Solutions
Online Inquiry
Global Services

CellRapeutics™ CIK Therapy Development Solutions

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CIK Therapy Development for Cancer Immunotherapy

Cytokine-induced killer (CIK) cell therapy represents a promising approach to cancer immunotherapy. CIK cells are a heterogeneous population comprising T cells, T-natural killer (NK) cells, and a minor fraction of NK cells that exhibit potent cytotoxic activity against tumor cells. They are characterized by their ability to mediate both T cell receptor-dependent and MHC-independent tumor cytotoxicity, which enhances their effectiveness across a diverse range of cancer types.

The therapeutic potential of CIK cells is underscored by their efficient and rapid expansion capabilities in culture, which allows for scalable manufacturing tailored to individual patient needs. Their mechanism of action involves a robust cytotoxic response through various pathways, including NKG2D, TRAIL, FasL, and DNAM-1, among others. This diversity in action mechanisms provides a compelling rationale for their use in combating relapse post-allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies.

Fig.1 Tumor recognition and anticancer activity of CIK cells.Fig.1 Mechanism of tumor recognition and anticancer activity of CIK cells.1

CIK Therapy Development Solutions at Creative Biolabs

At Creative Biolabs, we leverage our 20 years of expertise to offer advanced solutions for developing CIK cell therapy. Our approach is holistic, combining cutting-edge research with comprehensive service offerings that cater to the specific needs of our clients dealing with various cancer types.

Our services are underpinned by a robust understanding of the immunological underpinnings and clinical applications of CIK cells, enabling us to navigate and mitigate challenges in immunotherapy development effectively. By maintaining stringent adherence to good manufacturing practices (GMP)-compliant standards, we ensure that every therapeutic product or solution delivered is of the highest quality and efficacy.

Related Services

Creative Biolabs offers a full suite of services to facilitate the development of CIK therapies from concept to clinical application. Our offerings include:

CellRapeutics™ One-Stop CIK Therapy Development Services

Creative Biolabs provides one-stop services that cover every aspect of CIK cell therapy development. This includes the bespoke expansion protocols for CIK cells tailored to specific tumor types, ensuring optimal yield and potency. Our specialty lies in enhancing the specificity of CIK cells via genetic engineering and surface marker targeting, thus significantly reducing off-target effects and maximizing therapeutic outcomes.

CellRapeutics™ CIK Therapy Improvement Services

A cornerstone of our services is the improvement of CIK therapy through incorporating targeted strategies to enhance the efficacy of Cytokine-Induced Killer (CIK) cell therapy, combining CIK cells with other immunotherapies strategies, such as CAR-CIK development, DC-CIK development, dendritic cells (DCs), CIK combined with chemotherapy/radiotherapy development.

Benefits for You

Partnering with Creative Biolabs offers numerous advantages:

  • Tailored Solutions and Innovation: Our deep domain expertise ensures that therapeutic solutions are customized and optimized for efficacy, contributing to significant advancements in cancer immunotherapy.
  • Time and Cost Efficiency: By streamlining the development workflow and incorporating innovations such as IL-15 activation, product development times and costs are significantly reduced.
  • Quality and Safety: Our rigorous adherence to GMP standards and comprehensive assessment protocols guarantees high-quality, safe therapeutic products.

Frequently Asked Questions

Q1. Why choose CIK therapy over other immunotherapies?

A1: CIK therapy provides a unique combination of T and NK cell functionalities, enabling non-MHC-restricted cytotoxic activities which are crucial for targeting diverse tumor cells.

Q2. Can CIK cells be used for solid tumors as well as hematological malignancies?

A2: Yes, CIK cells have shown efficacy in both solid tumors and blood cancers, effectively targeting even chemo-resistant cancer stem cells, thereby broadening their therapeutic impact.

By providing these scientifically robust and operationally efficient CIK therapy development solutions, Creative Biolabs stands at the forefront of cancer immunotherapy innovation, empowering solutions that extend beyond the laboratory to impactful clinical applications.

Reference

  1. Li, Celine Man Ying, et al. "Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges." Cancer Treatment Reviews 122 (2024): 102665. Distributed under Open Access License CC BY 4.0, without modification.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.